RANCHO CUCAMONGA, Calif. - Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), currently trading near its 52-week low but showing strong financial health according to InvestingPro analysis, announced ...

Amphastar stated it will work with government leadership at various levels to ensure sustainable growth, workforce development, and alignment with economic and public health priorities.

Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar ®, BAQSIMI ®, Primatene MIST ®, REXTOVY TM, Amphadase ®, and Cortrosyn ®, are the ...

Amphastar Pharmaceuticals (NASDAQ: AMPH) stock reached a 52-week low, trading at 22.6 USD. According to InvestingPro analysis, the company appears undervalued despite maintaining strong ...

Amphastar Pharmaceuticals (NASDAQ: AMPH) stock reached a 52-week low, trading at 22.6 USD. According to InvestingPro analysis, the company appears undervalued despite maintaining strong fundamentals ...

Amphastar Pharmaceuticals' first quarter results saw revenue remain flat compared to last year and fall slightly short of Wall Street’s projections, while non-GAAP earnings per share came in ...

Q. I was prescribed pantoprazole for problems with Gastroesophageal reflux disease. When I took the first dose, it was like a miracle — my reflux symptoms disappeared overnight.

Dry powder inhalation (DPI) therapy offers effective treatment for pulmonary diseases, providing high drug delivery efficiency, minimal side effects, and enhanced patient compliance. The DPI efficacy ...